Canaccord Genuity Raises Price Target on Insulet Corporation (PODD) to $399, Maintains Buy Rating

With significant upside potential, Insulet Corporation (NASDAQ:PODD) secures a spot on our list of the 13 Best Quality Stocks to Buy According to Hedge Funds.

Canaccord Genuity Raises Price Target on Insulet Corporation (PODD) to $399, Maintains Buy Rating

On September 29, given Insulet Corporation (NASDAQ:PODD)’s dominant position in the insulin pump industry and its first-mover advantage in the type 2 diabetes market, Canaccord Genuity increased its price objective for the company from $353 to $399 while keeping its Buy rating.

The company revised its 2025 and 2026 revenue forecasts to account for growth potential and a slight increase in operating margin. In an effort to set the company apart and celebrate user independence with its tubeless device, Insulet Corporation (NASDAQ:PODD) and Pantone collaborated earlier this month to introduce “Omnipod Mango,” a vibrant tropical orange-yellow color for their Omnipod insulin pump.

The partnership highlights Insulet Corporation (NASDAQ:PODD)’s emphasis on innovation and the customer experience, and the company’s leadership in diabetes care solutions is further cemented by the ongoing high demand for its Omnipod system.

Insulet Corporation (NASDAQ:PODD) is a U.S. and international company that develops, produces, and markets insulin delivery devices for individuals with insulin-dependent diabetes. It is one of the best quality stocks.

While we acknowledge the potential of PODD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PODD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 12 Best Quantum Computing Stocks to Buy According to Wall Street Analysts.

Disclosure: None.